Edition:
United States

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

22.41USD
21 Aug 2018
Change (% chg)

-- (--)
Prev Close
$22.41
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
192,562
52-wk High
$43.98
52-wk Low
$13.85

Select another date:

Thu, Apr 19 2018

BRIEF-Adamas Announces Final Results From Phase 3 Open-Label Study Of Gocovri

* ADAMAS ANNOUNCES FINAL RESULTS FROM THE TWO-YEAR PHASE 3 OPEN-LABEL STUDY OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA

BRIEF-Adamas Announces First Patient Enrolled In Phase 3 Trial Of ADS 5102 In Multiple Sclerosis Patients With Walking Impairment

* 5102 IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT Source text for Eikon: Further company coverage:

BRIEF-Adamas Pharmaceuticals Announces Publication Of Data Supporting The Benefits Of Gocovri™ In Parkinson’s Disease Patients With Dyskinesia

* ADAMAS ANNOUNCES PUBLICATION OF DATA SUPPORTING THE BENEFITS OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA

BRIEF-Adamas Pharmaceuticals Says ‍As Of Feb 28, Co Received Prescriptions For Gocovri From About 390 Distinct Prescribers

* ADAMAS PHARMACEUTICALS SAYS ‍AS OF FEB 28, CO RECEIVED PRESCRIPTIONS FOR GOCOVRI FROM ABOUT 390 DISTINCT PRESCRIBERS - SEC FILING​

BRIEF-Adamas Q4 Loss Per Share $1.27

* ADAMAS REPORTS RECENT ACHIEVEMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2017

Select another date: